SlideShare une entreprise Scribd logo
1  sur  21
Télécharger pour lire hors ligne
HIGHLIGHTS FROM EXL PHARMA’S 2nd DIGITAL PHARMA EUROPE March 29-30, 2010 Berlin, Germany
‘We are living in the middle of the largest increase in expressive capability in the history of the human race’ Clay Shirkey, Here Comes Everybody, 2008
Ageing  populations Influence of  E7 countries Soaring cost of healthcare Pay for performance Influence of payers Patient  empowerment Personalized  medicine R&D not  delivering Fewer blockbusters Emphasis on prevention Catastrophic image of pharma Digitally-mediated behaviours
How do we  organizefor social  media?
What have we learnt  from mistakes?
How do we measure SM success or failure?
Approaching  the use of social media
A communication explosion Source: Tim Holden, digital creative @nothingelseis
8 in 10internet users go on-line for health information                   (KruResearch 2010) >1000facebook communities around chronic illnesses Social networks will become hugely  influential in patients‘ health decision making
Tipping the toes into the waters of web 2.0
Jump right in?                                                   Learn & understand Explore
Market and Competitor monitoring Exploration as PR tactic L.I.E.* Listen				 Inform			 Engage			 Market research tool Netnography *Kevin Kruse, KruResearch
Multiplier Effects in the Social Web 1 web posting published (active) 10 times commented (reactive) 1.000 times read (passive) Source: Nielsen BuzzMetrics
Basic Types of Web-based Research Use of the Social Web as an object of research and data source Use of web-based technology as a research tool Source: GIM Gesellschaft für Innovative Marktforschung, Germany
Netnography…. what is it about? Netnography is about listening closely to the Social Web: a qualitative method to systematically mine opinions, communicative patterns, moods and decision processes from online communication. Sources for Netnographyinclude all areas of the web containing user-generated content: blogs, forums, social networks, communities. Source: GIM Gesellschaft für Innovative Marktforschung, Germany
Still very new WEB 2.0: Lack of resources  24 / 7 Concerns about legal / regulatory  / competitor issues Acknowledgement that web 2.0 is growing in importance Useful market research tool
For discussion…..
For discussion…..
For discussion…..
For discussion…..
Want to attend next year’s conference? For additional information on ExL’s Digital Pharma Conferences, please visit www.exlpharma.com

Contenu connexe

Tendances

Stacey Trunnell Adv Ap Story App 2
Stacey Trunnell  Adv Ap Story App 2Stacey Trunnell  Adv Ap Story App 2
Stacey Trunnell Adv Ap Story App 2UTAdvertising
 
New Information Communication Technologies for Conflict Prevention and Manage...
New Information Communication Technologies for Conflict Prevention and Manage...New Information Communication Technologies for Conflict Prevention and Manage...
New Information Communication Technologies for Conflict Prevention and Manage...Angela-Jo Touza - Medina
 
Algorithms and Public Interest? Protecting pluralism and diversity in media a...
Algorithms and Public Interest? Protecting pluralism and diversity in media a...Algorithms and Public Interest? Protecting pluralism and diversity in media a...
Algorithms and Public Interest? Protecting pluralism and diversity in media a...University of Sydney
 
Eight Reality Checkpoints for Using "New Social Media" In Government
Eight Reality Checkpoints for Using "New Social Media" In GovernmentEight Reality Checkpoints for Using "New Social Media" In Government
Eight Reality Checkpoints for Using "New Social Media" In GovernmentDennis D. McDonald
 
ICT Solutions for Better Governance
ICT Solutions for Better GovernanceICT Solutions for Better Governance
ICT Solutions for Better GovernanceYannis Charalabidis
 
Osimo crossover-roadmap
Osimo crossover-roadmapOsimo crossover-roadmap
Osimo crossover-roadmaposimod
 
Interview With: James Musick Part 2
Interview With: James Musick Part 2Interview With: James Musick Part 2
Interview With: James Musick Part 2Amanda Boddington
 
MAC201 Technology and Media Audiences
MAC201 Technology and Media AudiencesMAC201 Technology and Media Audiences
MAC201 Technology and Media AudiencesRob Jewitt
 

Tendances (10)

Stacey Trunnell Adv Ap Story App 2
Stacey Trunnell  Adv Ap Story App 2Stacey Trunnell  Adv Ap Story App 2
Stacey Trunnell Adv Ap Story App 2
 
New Information Communication Technologies for Conflict Prevention and Manage...
New Information Communication Technologies for Conflict Prevention and Manage...New Information Communication Technologies for Conflict Prevention and Manage...
New Information Communication Technologies for Conflict Prevention and Manage...
 
Algorithms and Public Interest? Protecting pluralism and diversity in media a...
Algorithms and Public Interest? Protecting pluralism and diversity in media a...Algorithms and Public Interest? Protecting pluralism and diversity in media a...
Algorithms and Public Interest? Protecting pluralism and diversity in media a...
 
Eight Reality Checkpoints for Using "New Social Media" In Government
Eight Reality Checkpoints for Using "New Social Media" In GovernmentEight Reality Checkpoints for Using "New Social Media" In Government
Eight Reality Checkpoints for Using "New Social Media" In Government
 
Pubmedia 2.0 presentation
Pubmedia 2.0 presentationPubmedia 2.0 presentation
Pubmedia 2.0 presentation
 
ICT Solutions for Better Governance
ICT Solutions for Better GovernanceICT Solutions for Better Governance
ICT Solutions for Better Governance
 
Osimo crossover-roadmap
Osimo crossover-roadmapOsimo crossover-roadmap
Osimo crossover-roadmap
 
Big data, big stories big interventions :How evidence based stories influenc...
 Big data, big stories big interventions :How evidence based stories influenc... Big data, big stories big interventions :How evidence based stories influenc...
Big data, big stories big interventions :How evidence based stories influenc...
 
Interview With: James Musick Part 2
Interview With: James Musick Part 2Interview With: James Musick Part 2
Interview With: James Musick Part 2
 
MAC201 Technology and Media Audiences
MAC201 Technology and Media AudiencesMAC201 Technology and Media Audiences
MAC201 Technology and Media Audiences
 

En vedette

Intro to POInT Transformative Workshop
Intro to POInT Transformative WorkshopIntro to POInT Transformative Workshop
Intro to POInT Transformative WorkshopAl Cini
 
活动策划的3个阶段
活动策划的3个阶段活动策划的3个阶段
活动策划的3个阶段赵 强
 
Capitulo 2 - Microeconomía
Capitulo 2 - MicroeconomíaCapitulo 2 - Microeconomía
Capitulo 2 - Microeconomíamaricel
 
Lymphatic system and immunity
Lymphatic system and immunityLymphatic system and immunity
Lymphatic system and immunityM. Carol Carlisle
 
The fine line between self managing and anarchy 30 aug 2010
The fine line between self managing and anarchy 30 aug 2010The fine line between self managing and anarchy 30 aug 2010
The fine line between self managing and anarchy 30 aug 2010vseetara
 
Writing For The Media 12.11.10
Writing For The Media 12.11.10Writing For The Media 12.11.10
Writing For The Media 12.11.10WCG London
 
Boris Krstović - Choosing the Right Content Management System
Boris Krstović - Choosing the Right Content Management SystemBoris Krstović - Choosing the Right Content Management System
Boris Krstović - Choosing the Right Content Management Systemboccio
 
Seminario molecular
Seminario molecularSeminario molecular
Seminario molecularPablo Lara
 
Casestudy.starosta4000.final.graphics.fixed
Casestudy.starosta4000.final.graphics.fixedCasestudy.starosta4000.final.graphics.fixed
Casestudy.starosta4000.final.graphics.fixedCANDOO
 
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's  2nd Pharmaceutical Managed MarketsHighlights from ExL Pharma's  2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's 2nd Pharmaceutical Managed MarketsExL Pharma
 
2011 Kia Soul For Sale at Keffer Kia in Charlotte, North Carolina
2011 Kia Soul For Sale at Keffer Kia in Charlotte, North Carolina2011 Kia Soul For Sale at Keffer Kia in Charlotte, North Carolina
2011 Kia Soul For Sale at Keffer Kia in Charlotte, North CarolinaCourtney Boone
 
2012 Volkswagen Beetle review from edmunds
2012 Volkswagen Beetle review from edmunds2012 Volkswagen Beetle review from edmunds
2012 Volkswagen Beetle review from edmundsCourtney Boone
 
AIChE 2011 - Automatic Reaction Mechanism Generation with Group Additive Kine...
AIChE 2011 - Automatic Reaction Mechanism Generation with Group Additive Kine...AIChE 2011 - Automatic Reaction Mechanism Generation with Group Additive Kine...
AIChE 2011 - Automatic Reaction Mechanism Generation with Group Additive Kine...Richard West
 
活动执行流程
活动执行流程活动执行流程
活动执行流程赵 强
 
Highlights from ExL Pharma's 4th Latin America Clinical Trials
Highlights from  ExL Pharma's 4th Latin America Clinical TrialsHighlights from  ExL Pharma's 4th Latin America Clinical Trials
Highlights from ExL Pharma's 4th Latin America Clinical TrialsExL Pharma
 
Highlights from ExL Pharma's 5th Clinical Data Disclosure Summit
Highlights from ExL Pharma's 5th Clinical Data Disclosure SummitHighlights from ExL Pharma's 5th Clinical Data Disclosure Summit
Highlights from ExL Pharma's 5th Clinical Data Disclosure SummitExL Pharma
 

En vedette (20)

Intro to POInT Transformative Workshop
Intro to POInT Transformative WorkshopIntro to POInT Transformative Workshop
Intro to POInT Transformative Workshop
 
活动策划的3个阶段
活动策划的3个阶段活动策划的3个阶段
活动策划的3个阶段
 
Capitulo 2 - Microeconomía
Capitulo 2 - MicroeconomíaCapitulo 2 - Microeconomía
Capitulo 2 - Microeconomía
 
Lymphatic system and immunity
Lymphatic system and immunityLymphatic system and immunity
Lymphatic system and immunity
 
Trương Trung Nghĩa OB
Trương Trung Nghĩa OBTrương Trung Nghĩa OB
Trương Trung Nghĩa OB
 
Asesores contable claros & cia
Asesores contable claros & cia Asesores contable claros & cia
Asesores contable claros & cia
 
The fine line between self managing and anarchy 30 aug 2010
The fine line between self managing and anarchy 30 aug 2010The fine line between self managing and anarchy 30 aug 2010
The fine line between self managing and anarchy 30 aug 2010
 
Writing For The Media 12.11.10
Writing For The Media 12.11.10Writing For The Media 12.11.10
Writing For The Media 12.11.10
 
Marble
MarbleMarble
Marble
 
Boris Krstović - Choosing the Right Content Management System
Boris Krstović - Choosing the Right Content Management SystemBoris Krstović - Choosing the Right Content Management System
Boris Krstović - Choosing the Right Content Management System
 
Seminario molecular
Seminario molecularSeminario molecular
Seminario molecular
 
Casestudy.starosta4000.final.graphics.fixed
Casestudy.starosta4000.final.graphics.fixedCasestudy.starosta4000.final.graphics.fixed
Casestudy.starosta4000.final.graphics.fixed
 
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's  2nd Pharmaceutical Managed MarketsHighlights from ExL Pharma's  2nd Pharmaceutical Managed Markets
Highlights from ExL Pharma's 2nd Pharmaceutical Managed Markets
 
2011 Kia Soul For Sale at Keffer Kia in Charlotte, North Carolina
2011 Kia Soul For Sale at Keffer Kia in Charlotte, North Carolina2011 Kia Soul For Sale at Keffer Kia in Charlotte, North Carolina
2011 Kia Soul For Sale at Keffer Kia in Charlotte, North Carolina
 
Cardiovascular system
Cardiovascular systemCardiovascular system
Cardiovascular system
 
2012 Volkswagen Beetle review from edmunds
2012 Volkswagen Beetle review from edmunds2012 Volkswagen Beetle review from edmunds
2012 Volkswagen Beetle review from edmunds
 
AIChE 2011 - Automatic Reaction Mechanism Generation with Group Additive Kine...
AIChE 2011 - Automatic Reaction Mechanism Generation with Group Additive Kine...AIChE 2011 - Automatic Reaction Mechanism Generation with Group Additive Kine...
AIChE 2011 - Automatic Reaction Mechanism Generation with Group Additive Kine...
 
活动执行流程
活动执行流程活动执行流程
活动执行流程
 
Highlights from ExL Pharma's 4th Latin America Clinical Trials
Highlights from  ExL Pharma's 4th Latin America Clinical TrialsHighlights from  ExL Pharma's 4th Latin America Clinical Trials
Highlights from ExL Pharma's 4th Latin America Clinical Trials
 
Highlights from ExL Pharma's 5th Clinical Data Disclosure Summit
Highlights from ExL Pharma's 5th Clinical Data Disclosure SummitHighlights from ExL Pharma's 5th Clinical Data Disclosure Summit
Highlights from ExL Pharma's 5th Clinical Data Disclosure Summit
 

Similaire à Highlights from ExL Pharma's 2nd Digital Pharma Europe Conference

What's Next: The World of Fake News
What's Next: The World of Fake NewsWhat's Next: The World of Fake News
What's Next: The World of Fake NewsOgilvy Consulting
 
New Media Vs Traditional Media
New Media Vs Traditional MediaNew Media Vs Traditional Media
New Media Vs Traditional MediaLillykemmy
 
Convergence, Computation and Continuity: Challenges for PR in the 21st Century
Convergence, Computation and Continuity: Challenges for PR in the 21st CenturyConvergence, Computation and Continuity: Challenges for PR in the 21st Century
Convergence, Computation and Continuity: Challenges for PR in the 21st CenturySimon Collister & Associates
 
PresentationAnsgarZerfass
PresentationAnsgarZerfassPresentationAnsgarZerfass
PresentationAnsgarZerfassSerge Cornelus
 
Seth Grimes - Sentiment in Social Media
Seth Grimes - Sentiment in Social MediaSeth Grimes - Sentiment in Social Media
Seth Grimes - Sentiment in Social MediaInfluence People
 
A Study On The Changing Trends In Social Media And Its Impact Globally
A Study On The Changing Trends In Social Media And Its Impact GloballyA Study On The Changing Trends In Social Media And Its Impact Globally
A Study On The Changing Trends In Social Media And Its Impact GloballyAlicia Edwards
 
Wedf brochure (september)
Wedf brochure (september)Wedf brochure (september)
Wedf brochure (september)Morne Olivier
 
Jody iom future_ph_dec5
Jody iom future_ph_dec5Jody iom future_ph_dec5
Jody iom future_ph_dec5Jody Ranck
 
Jody Iom Future Ph Dec5
Jody Iom Future Ph Dec5Jody Iom Future Ph Dec5
Jody Iom Future Ph Dec5Jody Ranck
 
Pillars of the Digital Age [v4] #AXASocial
Pillars of the Digital Age [v4] #AXASocialPillars of the Digital Age [v4] #AXASocial
Pillars of the Digital Age [v4] #AXASocialMichael Netzley, Ph.D.
 
Debate 2.0 -- From Peer Review to Crowd Review
Debate 2.0 -- From Peer Review to Crowd ReviewDebate 2.0 -- From Peer Review to Crowd Review
Debate 2.0 -- From Peer Review to Crowd ReviewProf. Alexander Gerber
 
crowded space: a business case for social media?
crowded space: a business case for social media?crowded space: a business case for social media?
crowded space: a business case for social media?tony felice
 
Chapter 3 presentation
Chapter 3 presentation Chapter 3 presentation
Chapter 3 presentation Danno320
 
Chapter 3 presentation
Chapter 3 presentation Chapter 3 presentation
Chapter 3 presentation Sarah Pearson
 
Chapter 3 presentation
Chapter 3 presentation Chapter 3 presentation
Chapter 3 presentation voelkeld
 
Chapter 3 presentation
Chapter 3 presentation Chapter 3 presentation
Chapter 3 presentation Sarah Pearson
 

Similaire à Highlights from ExL Pharma's 2nd Digital Pharma Europe Conference (20)

What's Next: The World of Fake News
What's Next: The World of Fake NewsWhat's Next: The World of Fake News
What's Next: The World of Fake News
 
New Media Vs Traditional Media
New Media Vs Traditional MediaNew Media Vs Traditional Media
New Media Vs Traditional Media
 
The Triangulation of Truth
The Triangulation of TruthThe Triangulation of Truth
The Triangulation of Truth
 
Convergence, Computation and Continuity: Challenges for PR in the 21st Century
Convergence, Computation and Continuity: Challenges for PR in the 21st CenturyConvergence, Computation and Continuity: Challenges for PR in the 21st Century
Convergence, Computation and Continuity: Challenges for PR in the 21st Century
 
PresentationAnsgarZerfass
PresentationAnsgarZerfassPresentationAnsgarZerfass
PresentationAnsgarZerfass
 
Seth Grimes - Sentiment in Social Media
Seth Grimes - Sentiment in Social MediaSeth Grimes - Sentiment in Social Media
Seth Grimes - Sentiment in Social Media
 
Ws2011 giovannini
Ws2011 giovanniniWs2011 giovannini
Ws2011 giovannini
 
A Study On The Changing Trends In Social Media And Its Impact Globally
A Study On The Changing Trends In Social Media And Its Impact GloballyA Study On The Changing Trends In Social Media And Its Impact Globally
A Study On The Changing Trends In Social Media And Its Impact Globally
 
Wedf brochure (september)
Wedf brochure (september)Wedf brochure (september)
Wedf brochure (september)
 
mpifg_p10_13
mpifg_p10_13mpifg_p10_13
mpifg_p10_13
 
Jody iom future_ph_dec5
Jody iom future_ph_dec5Jody iom future_ph_dec5
Jody iom future_ph_dec5
 
Jody Iom Future Ph Dec5
Jody Iom Future Ph Dec5Jody Iom Future Ph Dec5
Jody Iom Future Ph Dec5
 
Pillars of the Digital Age [v4] #AXASocial
Pillars of the Digital Age [v4] #AXASocialPillars of the Digital Age [v4] #AXASocial
Pillars of the Digital Age [v4] #AXASocial
 
Debate 2.0 -- From Peer Review to Crowd Review
Debate 2.0 -- From Peer Review to Crowd ReviewDebate 2.0 -- From Peer Review to Crowd Review
Debate 2.0 -- From Peer Review to Crowd Review
 
crowded space: a business case for social media?
crowded space: a business case for social media?crowded space: a business case for social media?
crowded space: a business case for social media?
 
Chapter 3 presentation ope
Chapter 3 presentation opeChapter 3 presentation ope
Chapter 3 presentation ope
 
Chapter 3 presentation
Chapter 3 presentation Chapter 3 presentation
Chapter 3 presentation
 
Chapter 3 presentation
Chapter 3 presentation Chapter 3 presentation
Chapter 3 presentation
 
Chapter 3 presentation
Chapter 3 presentation Chapter 3 presentation
Chapter 3 presentation
 
Chapter 3 presentation
Chapter 3 presentation Chapter 3 presentation
Chapter 3 presentation
 

Plus de ExL Pharma

9th Medical Science Liaison Best Practices
9th Medical Science Liaison Best Practices9th Medical Science Liaison Best Practices
9th Medical Science Liaison Best PracticesExL Pharma
 
CMO Quality Oversight & Risk Management, April 2011, Boston
CMO Quality Oversight & Risk Management, April 2011, BostonCMO Quality Oversight & Risk Management, April 2011, Boston
CMO Quality Oversight & Risk Management, April 2011, BostonExL Pharma
 
13th Investigator Initiated Trials, April 2011, Basking Ridge, NJ
13th Investigator Initiated Trials, April 2011, Basking Ridge, NJ13th Investigator Initiated Trials, April 2011, Basking Ridge, NJ
13th Investigator Initiated Trials, April 2011, Basking Ridge, NJExL Pharma
 
2nd Annual Proactive GCP Compliance, April 2011, Arlington, VA
2nd Annual Proactive GCP Compliance, April 2011, Arlington, VA2nd Annual Proactive GCP Compliance, April 2011, Arlington, VA
2nd Annual Proactive GCP Compliance, April 2011, Arlington, VAExL Pharma
 
The 3rd Annual Digital Pharma Europe, March 2011, Ingelheim, Germany
The 3rd Annual Digital Pharma Europe, March 2011, Ingelheim, GermanyThe 3rd Annual Digital Pharma Europe, March 2011, Ingelheim, Germany
The 3rd Annual Digital Pharma Europe, March 2011, Ingelheim, GermanyExL Pharma
 
6th Annual Support for Independent Medical Education, March 2011, New York City
6th Annual Support for Independent Medical Education, March 2011, New York City6th Annual Support for Independent Medical Education, March 2011, New York City
6th Annual Support for Independent Medical Education, March 2011, New York CityExL Pharma
 
5th Forecasting and Optimizing the Clinical Supply Chain, March 2011, Philade...
5th Forecasting and Optimizing the Clinical Supply Chain, March 2011, Philade...5th Forecasting and Optimizing the Clinical Supply Chain, March 2011, Philade...
5th Forecasting and Optimizing the Clinical Supply Chain, March 2011, Philade...ExL Pharma
 
4th Lean Sigma & Kaizen for Pharma R&D Conference, March 2011, Miami
4th Lean Sigma & Kaizen for Pharma R&D Conference, March 2011, Miami4th Lean Sigma & Kaizen for Pharma R&D Conference, March 2011, Miami
4th Lean Sigma & Kaizen for Pharma R&D Conference, March 2011, MiamiExL Pharma
 
6th Clinical Data Disclosure Summit, March 2011, Philadelphia
6th Clinical Data Disclosure Summit, March 2011, Philadelphia6th Clinical Data Disclosure Summit, March 2011, Philadelphia
6th Clinical Data Disclosure Summit, March 2011, PhiladelphiaExL Pharma
 
2nd Annual Clinical Site Feasibility, Selection, and Startup, March 2011, Phi...
2nd Annual Clinical Site Feasibility, Selection, and Startup, March 2011, Phi...2nd Annual Clinical Site Feasibility, Selection, and Startup, March 2011, Phi...
2nd Annual Clinical Site Feasibility, Selection, and Startup, March 2011, Phi...ExL Pharma
 
6th Latin America Clinical Trials Conference, March 2011, Philadelphia
6th Latin America Clinical Trials Conference, March 2011, Philadelphia6th Latin America Clinical Trials Conference, March 2011, Philadelphia
6th Latin America Clinical Trials Conference, March 2011, PhiladelphiaExL Pharma
 
2nd Patient Engagement Summit: New Technologies for Engaging Patients in Clin...
2nd Patient Engagement Summit: New Technologies for Engaging Patients in Clin...2nd Patient Engagement Summit: New Technologies for Engaging Patients in Clin...
2nd Patient Engagement Summit: New Technologies for Engaging Patients in Clin...ExL Pharma
 
Highlights from ExL Pharma's 12th Investigator Initiated Trials
Highlights from ExL Pharma's 12th Investigator Initiated TrialsHighlights from ExL Pharma's 12th Investigator Initiated Trials
Highlights from ExL Pharma's 12th Investigator Initiated TrialsExL Pharma
 
Highlights from ExL Pharma's 6th MSL Best Practices
Highlights from ExL Pharma's 6th MSL Best PracticesHighlights from ExL Pharma's 6th MSL Best Practices
Highlights from ExL Pharma's 6th MSL Best PracticesExL Pharma
 
Highlights from ExL Pharma's Proactive GCP Compliance
Highlights from ExL Pharma's Proactive GCP ComplianceHighlights from ExL Pharma's Proactive GCP Compliance
Highlights from ExL Pharma's Proactive GCP ComplianceExL Pharma
 
Highlights from ExL Pharma's 3rd Lean Sigma & Kaizen
Highlights from ExL Pharma's 3rd Lean Sigma & KaizenHighlights from ExL Pharma's 3rd Lean Sigma & Kaizen
Highlights from ExL Pharma's 3rd Lean Sigma & KaizenExL Pharma
 
Highlights from ExL Pharma's 4th Clinical Billing & Research Compliance
Highlights from ExL Pharma's 4th Clinical Billing & Research ComplianceHighlights from ExL Pharma's 4th Clinical Billing & Research Compliance
Highlights from ExL Pharma's 4th Clinical Billing & Research ComplianceExL Pharma
 
Highlights from ExL Pharma's 5th Data Monitoring Committees
Highlights from ExL Pharma's 5th Data Monitoring CommitteesHighlights from ExL Pharma's 5th Data Monitoring Committees
Highlights from ExL Pharma's 5th Data Monitoring CommitteesExL Pharma
 
Highlights from ExL Pharma's Site Selection, Activation & Communication
Highlights from ExL Pharma's Site Selection, Activation & CommunicationHighlights from ExL Pharma's Site Selection, Activation & Communication
Highlights from ExL Pharma's Site Selection, Activation & CommunicationExL Pharma
 
Highlights from ExL Pharma’s 2nd Annual Patient Assistance Programs
Highlights from ExL Pharma’s 2nd Annual Patient Assistance ProgramsHighlights from ExL Pharma’s 2nd Annual Patient Assistance Programs
Highlights from ExL Pharma’s 2nd Annual Patient Assistance ProgramsExL Pharma
 

Plus de ExL Pharma (20)

9th Medical Science Liaison Best Practices
9th Medical Science Liaison Best Practices9th Medical Science Liaison Best Practices
9th Medical Science Liaison Best Practices
 
CMO Quality Oversight & Risk Management, April 2011, Boston
CMO Quality Oversight & Risk Management, April 2011, BostonCMO Quality Oversight & Risk Management, April 2011, Boston
CMO Quality Oversight & Risk Management, April 2011, Boston
 
13th Investigator Initiated Trials, April 2011, Basking Ridge, NJ
13th Investigator Initiated Trials, April 2011, Basking Ridge, NJ13th Investigator Initiated Trials, April 2011, Basking Ridge, NJ
13th Investigator Initiated Trials, April 2011, Basking Ridge, NJ
 
2nd Annual Proactive GCP Compliance, April 2011, Arlington, VA
2nd Annual Proactive GCP Compliance, April 2011, Arlington, VA2nd Annual Proactive GCP Compliance, April 2011, Arlington, VA
2nd Annual Proactive GCP Compliance, April 2011, Arlington, VA
 
The 3rd Annual Digital Pharma Europe, March 2011, Ingelheim, Germany
The 3rd Annual Digital Pharma Europe, March 2011, Ingelheim, GermanyThe 3rd Annual Digital Pharma Europe, March 2011, Ingelheim, Germany
The 3rd Annual Digital Pharma Europe, March 2011, Ingelheim, Germany
 
6th Annual Support for Independent Medical Education, March 2011, New York City
6th Annual Support for Independent Medical Education, March 2011, New York City6th Annual Support for Independent Medical Education, March 2011, New York City
6th Annual Support for Independent Medical Education, March 2011, New York City
 
5th Forecasting and Optimizing the Clinical Supply Chain, March 2011, Philade...
5th Forecasting and Optimizing the Clinical Supply Chain, March 2011, Philade...5th Forecasting and Optimizing the Clinical Supply Chain, March 2011, Philade...
5th Forecasting and Optimizing the Clinical Supply Chain, March 2011, Philade...
 
4th Lean Sigma & Kaizen for Pharma R&D Conference, March 2011, Miami
4th Lean Sigma & Kaizen for Pharma R&D Conference, March 2011, Miami4th Lean Sigma & Kaizen for Pharma R&D Conference, March 2011, Miami
4th Lean Sigma & Kaizen for Pharma R&D Conference, March 2011, Miami
 
6th Clinical Data Disclosure Summit, March 2011, Philadelphia
6th Clinical Data Disclosure Summit, March 2011, Philadelphia6th Clinical Data Disclosure Summit, March 2011, Philadelphia
6th Clinical Data Disclosure Summit, March 2011, Philadelphia
 
2nd Annual Clinical Site Feasibility, Selection, and Startup, March 2011, Phi...
2nd Annual Clinical Site Feasibility, Selection, and Startup, March 2011, Phi...2nd Annual Clinical Site Feasibility, Selection, and Startup, March 2011, Phi...
2nd Annual Clinical Site Feasibility, Selection, and Startup, March 2011, Phi...
 
6th Latin America Clinical Trials Conference, March 2011, Philadelphia
6th Latin America Clinical Trials Conference, March 2011, Philadelphia6th Latin America Clinical Trials Conference, March 2011, Philadelphia
6th Latin America Clinical Trials Conference, March 2011, Philadelphia
 
2nd Patient Engagement Summit: New Technologies for Engaging Patients in Clin...
2nd Patient Engagement Summit: New Technologies for Engaging Patients in Clin...2nd Patient Engagement Summit: New Technologies for Engaging Patients in Clin...
2nd Patient Engagement Summit: New Technologies for Engaging Patients in Clin...
 
Highlights from ExL Pharma's 12th Investigator Initiated Trials
Highlights from ExL Pharma's 12th Investigator Initiated TrialsHighlights from ExL Pharma's 12th Investigator Initiated Trials
Highlights from ExL Pharma's 12th Investigator Initiated Trials
 
Highlights from ExL Pharma's 6th MSL Best Practices
Highlights from ExL Pharma's 6th MSL Best PracticesHighlights from ExL Pharma's 6th MSL Best Practices
Highlights from ExL Pharma's 6th MSL Best Practices
 
Highlights from ExL Pharma's Proactive GCP Compliance
Highlights from ExL Pharma's Proactive GCP ComplianceHighlights from ExL Pharma's Proactive GCP Compliance
Highlights from ExL Pharma's Proactive GCP Compliance
 
Highlights from ExL Pharma's 3rd Lean Sigma & Kaizen
Highlights from ExL Pharma's 3rd Lean Sigma & KaizenHighlights from ExL Pharma's 3rd Lean Sigma & Kaizen
Highlights from ExL Pharma's 3rd Lean Sigma & Kaizen
 
Highlights from ExL Pharma's 4th Clinical Billing & Research Compliance
Highlights from ExL Pharma's 4th Clinical Billing & Research ComplianceHighlights from ExL Pharma's 4th Clinical Billing & Research Compliance
Highlights from ExL Pharma's 4th Clinical Billing & Research Compliance
 
Highlights from ExL Pharma's 5th Data Monitoring Committees
Highlights from ExL Pharma's 5th Data Monitoring CommitteesHighlights from ExL Pharma's 5th Data Monitoring Committees
Highlights from ExL Pharma's 5th Data Monitoring Committees
 
Highlights from ExL Pharma's Site Selection, Activation & Communication
Highlights from ExL Pharma's Site Selection, Activation & CommunicationHighlights from ExL Pharma's Site Selection, Activation & Communication
Highlights from ExL Pharma's Site Selection, Activation & Communication
 
Highlights from ExL Pharma’s 2nd Annual Patient Assistance Programs
Highlights from ExL Pharma’s 2nd Annual Patient Assistance ProgramsHighlights from ExL Pharma’s 2nd Annual Patient Assistance Programs
Highlights from ExL Pharma’s 2nd Annual Patient Assistance Programs
 

Highlights from ExL Pharma's 2nd Digital Pharma Europe Conference

  • 1. HIGHLIGHTS FROM EXL PHARMA’S 2nd DIGITAL PHARMA EUROPE March 29-30, 2010 Berlin, Germany
  • 2. ‘We are living in the middle of the largest increase in expressive capability in the history of the human race’ Clay Shirkey, Here Comes Everybody, 2008
  • 3. Ageing populations Influence of E7 countries Soaring cost of healthcare Pay for performance Influence of payers Patient empowerment Personalized medicine R&D not delivering Fewer blockbusters Emphasis on prevention Catastrophic image of pharma Digitally-mediated behaviours
  • 4. How do we organizefor social media?
  • 5. What have we learnt from mistakes?
  • 6. How do we measure SM success or failure?
  • 7. Approaching the use of social media
  • 8. A communication explosion Source: Tim Holden, digital creative @nothingelseis
  • 9. 8 in 10internet users go on-line for health information (KruResearch 2010) >1000facebook communities around chronic illnesses Social networks will become hugely influential in patients‘ health decision making
  • 10. Tipping the toes into the waters of web 2.0
  • 11. Jump right in? Learn & understand Explore
  • 12. Market and Competitor monitoring Exploration as PR tactic L.I.E.* Listen Inform Engage Market research tool Netnography *Kevin Kruse, KruResearch
  • 13. Multiplier Effects in the Social Web 1 web posting published (active) 10 times commented (reactive) 1.000 times read (passive) Source: Nielsen BuzzMetrics
  • 14. Basic Types of Web-based Research Use of the Social Web as an object of research and data source Use of web-based technology as a research tool Source: GIM Gesellschaft für Innovative Marktforschung, Germany
  • 15. Netnography…. what is it about? Netnography is about listening closely to the Social Web: a qualitative method to systematically mine opinions, communicative patterns, moods and decision processes from online communication. Sources for Netnographyinclude all areas of the web containing user-generated content: blogs, forums, social networks, communities. Source: GIM Gesellschaft für Innovative Marktforschung, Germany
  • 16. Still very new WEB 2.0: Lack of resources 24 / 7 Concerns about legal / regulatory / competitor issues Acknowledgement that web 2.0 is growing in importance Useful market research tool
  • 21. Want to attend next year’s conference? For additional information on ExL’s Digital Pharma Conferences, please visit www.exlpharma.com